1. Scrip
  2. >>Business

After An Upbeat J.P. Morgan, Three Biopharmas Look To Kick Off IPOs For 2024

 
• By Andrew McConaghie

Gene editing company Metagenomi and two oncology biopharmas will test the IPO waters soon – with hopes this could pave the way for others.

Share price movement
• Source: Shutterstock

2023 was another tough year for biotech initial public offerings, but there are some signs that 2024 could see the market open up again. After a more upbeat mood at the J.P. Morgan conference (JPM) and signs of improving macro-economic stability, the next big test for biotech is a trio of planned flotations. These will come from gene-editing specialist Metagenomi and cancer-focused start-ups ArriVent Biopharma and CG Oncology.

Key Takeaways

  • After two tough years for early-stage biotech, there are signs IPOs and other funding could revive in 2024

  • Metagenomi has not reached Phase I yet, but Arrivent and CG Oncology are both in Phase III studies

All three IPO filings were made ahead of the annual San Francisco investor conference which took place this week, but if a buoyant JPM mood persists, this could boost

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.